about
Drug discovery and human African trypanosomiasis: a disease less neglected?6-Arylpyrazine-2-carboxamides: A New Core for Trypanosoma brucei Inhibitors.Pyridyl benzamides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei.3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasis.Hit-to-Lead Optimization of a Novel Class of Potent, Broad-Spectrum Trypanosomacides.The Importance of Collaboration between Industry, Academics, and Nonprofits in Tropical Disease Drug Discovery.Optimization of Physicochemical Properties for 4-Anilinoquinoline Inhibitors of Plasmodium falciparum Proliferation.The Future of Chemistry is GlobalMetabolomics and lipidomics reveal perturbation of sphingolipid metabolism by a novel anti-trypanosomal 3-(oxazolo[4,5-b]pyridine-2-yl)anilidePAINS: Relevance to Tool Compound Discovery and Fragment-Based ScreeningAnilinoquinoline based inhibitors of trypanosomatid proliferationEvaluation of a class of isatinoids identified from a high-throughput screen of human kinase inhibitors as anti-Sleeping Sickness agentsDiscovery of Potent N-Ethylurea Pyrazole Derivatives as Dual Inhibitors of Trypanosoma brucei and Trypanosoma cruziImprovement of Aqueous Solubility of Lapatinib-Derived Analogues: Identification of a Quinolinimine Lead for Human African Trypanosomiasis Drug DevelopmentHit-to-Lead Optimization of Benzoxazepinoindazoles As Human African Trypanosomiasis TherapeuticsSelectivity and Physicochemical Optimization of Repurposed Pyrazolo[1,5-b]pyridazines for the Treatment of Human African Trypanosomiasis
P50
Q38154344-42B04C14-0338-483F-AFC6-B9134BD5585CQ38845969-47C4C86C-408E-41A2-B4D6-38633C26FCCBQ38979683-10281568-FDC3-4DDA-BC8E-47678BF8965EQ39003623-D526DE1D-FF27-4E6F-8A5F-65B070B39359Q39414703-E4CB437A-E0E5-4F53-963B-0F3A1173B275Q45305437-69814141-963D-4753-BDE6-ACF223E5029FQ48020714-D9D6E55E-1C10-4A0A-B61F-43AA8ED8D012Q57414079-EC1BDDA9-1F47-4880-B604-FFD97B75A1D3Q58852782-DCB172FF-4979-48D7-97BF-20C1BD3A054AQ58854342-B3254403-4BC1-4713-B706-B5D51C638EE3Q60050737-05545D8B-7142-48C6-8E42-28D2B1B98237Q64265985-196E7552-351E-470D-AAAB-A57CD67C39C5Q70977039-9C58D8C8-1715-4055-BA44-FD0F24EBDBB2Q90631946-53420687-DCAA-40C6-B854-7D7B9AE9A5F9Q91034135-39F69D60-ECEA-4130-8EDC-02D6D5CC7860Q92044327-13B1B43A-E392-4033-8A87-AF7D88A48173
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Lori Ferrins
@ast
Lori Ferrins
@en
Lori Ferrins
@es
Lori Ferrins
@nl
Lori Ferrins
@sl
type
label
Lori Ferrins
@ast
Lori Ferrins
@en
Lori Ferrins
@es
Lori Ferrins
@nl
Lori Ferrins
@sl
prefLabel
Lori Ferrins
@ast
Lori Ferrins
@en
Lori Ferrins
@es
Lori Ferrins
@nl
Lori Ferrins
@sl
P106
P1153
55785223900
P2002
LoriFerrins
P21
P31
P496
0000-0001-8992-0919
P569
2000-01-01T00:00:00Z